LLY

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia, Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement

Retrieved on: 
Tuesday, November 29, 2022
Cancer, Multimedia, Lilly, Biotechnology, NYSE, Eli Lilly and Company, LLY, Alzheimer's disease, Chemistry, Obesity, Pharmaceutical industry

INDIANAPOLIS, Nov. 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022.

Key Points: 
  • INDIANAPOLIS, Nov. 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022.
  • Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance.
  • The conference call will begin at 9 a.m. Eastern time.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.

Lilly to Participate in Evercore ISI HealthCONx Conference

Retrieved on: 
Wednesday, November 16, 2022
Cancer, Conference, Obesity, Biotechnology, Eli Lilly and Company, NYSE, Multimedia, LLY, CEO, Alzheimer's disease, Chemistry, Solution, Pharmaceutical industry, Facebook, Lilly

INDIANAPOLIS, Nov. 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attendthe fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022.Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman, M.D., chief medical officer, Loxo@Lilly, will participate in a fireside chat at 12:10 p.m., Eastern time.

Key Points: 
  • INDIANAPOLIS, Nov. 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attendthe fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022.Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman, M.D., chief medical officer, Loxo@Lilly, will participate in a fireside chat at 12:10 p.m., Eastern time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 90 days.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

Retrieved on: 
Monday, November 14, 2022
BMY, PDAC, Merrimack Pharmaceuticals, TSX, RNA transfection, Idleness, Mortality, ORR, The New England Journal of Medicine, BioNTech, Irinotecan, Oncolytics Biotech, News, Hoffmann-La Roche, BNTX, Cancer, CBR, Eli Lilly and Company, FDA, Entrepreneurship, BMS, Optimism, Survival, Research, NYSE, Lenalidomide, Pancreatic cancer, LLY, Bristol Myers Squibb, Celgene, Rituximab, Profile, Patient, Breast, CEO, NASDAQ, CR, ONC, SITC, PD-L1, OTC, Lung, Letter, Ipsen, OTCQX, Pharmaceutical industry, Genentech, Pelareorep, Gemcitabine

VANCOUVER, British Colombia, Nov. 14, 2022 /PRNewswire/ -- USA News Group  -  English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his victory over pancreatic cancer, known as the world's deadliest common cancer. "The good news is that we are starting to fight back," said Idle after creating the Bright Side Fund to support research and help promote early detection. Despite US cancer death rates being down across all age groups, however mortality rates for pancreatic cancers have gone up, so there's much work to be done. Now there's developments in the fight against pancreatic cancer coming that are generating huge amounts of optimism from biotech groups such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Roche Holding AG (OTCQX: RHHBY), Eli Lilly and Company (NYSE: LLY), Bristol-Myers Squibb Company (NYSE: BMY), and BioNTech SE (NASDAQ: BNTX).

Key Points: 
  • One of the most promising new data sets in pancreatic cancer therapies is coming from pelareorep, developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC).
  • Highlighting the impressive significance of the data, Oncolytics Biotech cites the Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine study published in 2013 by Dr.
  • Back in June, Oncolytics Biotech announced it had achieved success criteria for efficacy in its pancreatic cancer cohort.
  • Back in June, BioNTech presented preliminary Phase I data of its BNT122, evaluating with Genentech (a Roche subsidiary) in pancreatic cancer.

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

Retrieved on: 
Monday, November 14, 2022
BMY, PDAC, Merrimack Pharmaceuticals, TSX, RNA transfection, Idleness, Mortality, ORR, The New England Journal of Medicine, BioNTech, Irinotecan, Oncolytics Biotech, News, Hoffmann-La Roche, BNTX, Cancer, CBR, Eli Lilly and Company, FDA, Entrepreneurship, BMS, Optimism, Survival, Research, NYSE, Lenalidomide, Pancreatic cancer, LLY, Bristol Myers Squibb, Celgene, Rituximab, Profile, Patient, Breast, CEO, NASDAQ, CR, ONC, SITC, PD-L1, OTC, Lung, Letter, Ipsen, OTCQX, Pharmaceutical industry, Genentech, Pelareorep, Gemcitabine

VANCOUVER, British Colombia, Nov. 14, 2022 /PRNewswire/ -- USA News Group  -  English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his victory over pancreatic cancer, known as the world's deadliest common cancer. "The good news is that we are starting to fight back," said Idle after creating the Bright Side Fund to support research and help promote early detection. Despite US cancer death rates being down across all age groups, however mortality rates for pancreatic cancers have gone up, so there's much work to be done. Now there's developments in the fight against pancreatic cancer coming that are generating huge amounts of optimism from biotech groups such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Roche Holding AG (OTCQX: RHHBY), Eli Lilly and Company (NYSE: LLY), Bristol-Myers Squibb Company (NYSE: BMY), and BioNTech SE (NASDAQ: BNTX).

Key Points: 
  • One of the most promising new data sets in pancreatic cancer therapies is coming from pelareorep, developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC).
  • Highlighting the impressive significance of the data, Oncolytics Biotech cites the Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine study published in 2013 by Dr.
  • Back in June, Oncolytics Biotech announced it had achieved success criteria for efficacy in its pancreatic cancer cohort.
  • Back in June, BioNTech presented preliminary Phase I data of its BNT122, evaluating with Genentech (a Roche subsidiary) in pancreatic cancer.

Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Infection, Drug discovery, NYSE, Eli Lilly and Company, Private Securities Litigation Reform Act, Cancer, Lists of diseases, Marketing, Solution, Diabetes, News, Industry, Faculty, Form, Chemistry, WEST, Instagram, Inflammation, Family, Organization, LinkedIn, Patient, Engineering, Obesity, Population, Student, LLY, Education, Integrative neuroscience, Research, U.S. Securities and Exchange Commission, Physiology, CEO, U.S. News & World Report, Interdisciplinarity, Alzheimer's disease, Twitter, Tutoring, Pharmaceutical industry, Medicine, Facebook, Purdue University, Lilly

INDIANAPOLIS and WEST LAFAYETTE, Ind., Oct. 27, 2022 /PRNewswire/ -- Purdue University and Eli Lilly and Company (NYSE: LLY) are establishing an innovative new pharmaceutical manufacturing scholarship program and have renewed their strategic research collaboration in a series of moves that will expand their impact in Indiana and improve lives on a global scale. Lilly has committed $92.5 million to the West Lafayette campus through these two programs.

Key Points: 
  • Through these collaborations, Lilly and Purdue are helping to build a critical pharmaceutical ecosystem in the heartland," said Purdue President Mitch Daniels.
  • The Lilly Scholars program will provide participating students with preferred access and opportunities to compete for a role at the company following graduation.
  • The organizations entered into a new strategic research collaboration in 2017, funded by an initial $50 million commitment from Lilly.
  • Both Lilly and Purdue have made strategic commitments in recent years to strengthen expertise and programs in bioscience areas, including pharmaceutical manufacturing.

Humankind Investments Ranks Top 100 U.S. Companies Creating Most Value for Society

Retrieved on: 
Tuesday, October 25, 2022
Finance, Consulting, Environmental, Social and Governance (ESG), Environment, Professional Services, Quality of life, Health, LLY, NGO, Investment, AbbVie, PFE, ESG, Johnson & Johnson, Human, ABBV, Â, Technology, Social, BMY, CEO, Water, JNJ, PG, Food, Eli Lilly and Company, MSFT, Accounting, Microsoft, Internet, High-net-worth individual, Bristol Myers Squibb, MRK, GOOGL, Merck & Co., Procter & Gamble, VZ, Consumer value, Social Security Government Pension Offset, Risk management, Pharmaceutical industry, Biophysical environment, Pfizer, Verizon Communications

Humankind Investments , a quantitatively driven asset manager specializing in socially responsible investments, announced today the release of the Humankind 100, the first-ever ranking of the top U.S. companies offering the greatest benefit to humanity, based on Humankind Investments proprietary Humankind Value methodology.

Key Points: 
  • Humankind Investments , a quantitatively driven asset manager specializing in socially responsible investments, announced today the release of the Humankind 100, the first-ever ranking of the top U.S. companies offering the greatest benefit to humanity, based on Humankind Investments proprietary Humankind Value methodology.
  • We launched the Humankind 100 with a two-fold purpose to help people understand the companies best supporting their quality of life and to encourage companies to continue striving for progress, said James Katz, founder and CEO of Humankind Investments.
  • The ranking was calculated using Humankind Investments proprietary Humankind Value methodology, which tends to favor companies that promote human health and improved quality of life.
  • A companys Humankind Value, an estimate of how much value the company creates for humankind, is published annually and is current as of April 29, 2022.

Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement

Retrieved on: 
Wednesday, October 19, 2022
LinkedIn, LLY, Lilly, NYSE, Biotechnology, Twitter, Instagram, Eli Lilly and Company, Multimedia, Lists of diseases, Obesity, Alzheimer's disease, Chemistry, Solution, Cancer, Pharmaceutical industry, Facebook

INDIANAPOLIS, Oct. 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022.

Key Points: 
  • INDIANAPOLIS, Oct. 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022.
  • Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
  • The conference call will begin at 9 a.m. Eastern time.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.

AKOUOS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS

Retrieved on: 
Wednesday, October 19, 2022
Class Action Lawsuit, Professional Services, Legal, LLC, AKUS, NYSE, Time, Nasdaq, LLY, Sale, Eli Lilly and Company, CVR, KSF, Company, Akouo

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Akouos, Inc. (NasdaqGS: AKUS) to Eli Lilly and Company (NYSE: LLY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Akouos, Inc. (NasdaqGS: AKUS) to Eli Lilly and Company (NYSE: LLY).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .